Home JAK/STAT JAK inhibitor AZD1480 仅限科研使用

AZD1480

AZD1480是一种新型，ATP竞争性的JAK2抑制剂，无细胞试验中IC50为0.26 nM，选择性作用于JAK3和Tyk2，对JAK1的作用较弱。Phase 1。

AZD1480 Chemical Structure

AZD1480 Chemical Structure

CAS: 935666-88-9

规格 价格 库存 购买数量
10mM (1mL in DMSO) 1071.19 现货
5mg 819.48 现货
50mg 4671.71 现货
200mg 12858.3 现货
1g 43161.3 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn
免费分装
免费预溶

AZD1480相关产品

相关信号通路图

JAK Signaling Pathways

JAK信号通路图

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息(PMID)
NCI-H82 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
GLC4 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
NCI-N592 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
NCI-H82 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
GLC4 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
NCI-N592 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
CWR22Rv1 Function Assay 800 nM 72 h suppresses IL-6-induced migratory 24577942
DU145  Function Assay 800 nM 72 h suppresses IL-6-induced migratory 24577942
DU145  Function Assay 0-200 nM 1 h  suppresses IL-6-activated Stat3 and ERK1/2 signaling 24577942
MO4 Function Assay 0.5/1/5 μM 6 h inhibits P-STAT3 expression  25149535
OVCAR-8  Apoptosis Assay 0.5/1/5 μM 48 h induces significant apoptosis at high concerntration 25646015
OVCAR-5  Apoptosis Assay 0.5/1/5 μM 48 h induces significant apoptosis at high concerntration 25646015
OVCAR-8  Cell Viability Assay 0.05-10 μM 72 h reduces cell viability at the concerntration of 5 μM 25646015
OVCAR-5 Cell Viability Assay 0.05-10 μM 72 h reduces cell viability at the concerntration of 5 μM 25646015
A1847 Cell Viability Assay 0.05-10 μM 72 h reduces cell viability at the concerntration of 5 μM 25646015
MOVCAR-5009 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
MOVCAR-5447 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
OVCAR-8 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
OVCAR-5 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
A1847 Function Assay 0.05-10 μM 24 h reduces phosphorylated STAT3 levels 25646015
UM-22A Function Assay 0.0005-1.6 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
HH5 Function Assay 0.0005-3.8 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
Cal33 Function Assay 0.0005-3.8 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
UMSCC-1 Function Assay 0.0005-1.6 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
LoVo  Function Assay 5 μM 48 h blocks JAK2/STAT3 signaling 25954974
SW620 Function Assay 5 μM 48 h blocks JAK2/STAT3 signaling 25954974
KCNR Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
SY5Y Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
Rh18 Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
TC32 Apoptosis Assay 0.5/1.0/2.5 μM 24 h induces an increase in caspase 3/7 activity 23531921
KCNR Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
SY5Y Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
Rh18 Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
TC32 Function Assay 0.5/1.0/2.5/5 μM 24 h inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
TPC-1 Growth Inhibition Assay 1 µM 0-4 d inhibits cell growth after 2 d treatment 23056499
MZ-CRC1  Growth Inhibition Assay 1 µM 0-5 d inhibits cell growth after 1 d treatment 23056499
TT  Growth Inhibition Assay 1 µM 0-4 d inhibits cell growth after 1 d treatment 23056499
TPC-1 Function Assay 1 µM 72 h induces G1 blockage 23056499
MZ-CRC1  Function Assay 1 µM 72 h induces G1 blockage 23056499
TT  Function Assay 1 µM 72 h induces G1 blockage 23056499
MZ-CRC1  Apoptosis Assay 1 µM 48 h induces apoptosis 23056499
TT  Apoptosis Assay 1 µM 48 h induces apoptosis 23056499
HD-LM2 Function Assay 0.1/0.5/1/5 μM 72 h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
L-428 Function Assay 0.1/0.5/1/5 μM 72 h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
KM-H2 Function Assay 0.1/0.5/1/5 μM 72 h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
L-540 Function Assay 0.1/0.5/1/5 μM 72 h inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
HD-LM2 Apoptosis Assay 1/5 μM 72 h induces apoptosis 22829094
L-428 Apoptosis Assay 1/5 μM 72 h induces apoptosis 22829094
KM-H2 Apoptosis Assay 1/5 μM 72 h induces apoptosis 22829094
L-540 Apoptosis Assay 1/5 μM 72 h induces apoptosis 22829094
U251-MG Function Assay 1 µM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
U87-MG Function Assay 1 µM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
4C8 Function Assay 1 µM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
U251-MG Growth Inhibition Assay 1/10 µM 24/48/72 h inhibits cell proliferation at a concentration of 10 µM 22027691
U87-MG Growth Inhibition Assay 1/10 µM 24/48/72 h inhibits cell proliferation at a concentration of 10 µM 22027691
4C8 Growth Inhibition Assay 1/10 µM 24/48/72 h inhibits cell proliferation at a concentration of 10 µM 22027691
U266 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
Kms.11 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
8226 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
SW620 Cell cycle assay 3.3 uM 24 hrs Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase at 3.3 uM after 24 hrs by flow cytometry 21138246
HEL Function assay 0.3 uM 5 mins Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting 21138246
HEL Function assay 0.3 uM 30 to 60 mins Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting 21138246
BA/F3 Antitumor assay 30 mg/kg 12 hrs Antitumor activity against mouse BA/F3 cells expressing Tel-JAK2 xenografted in NCr mouse assessed as reduction of phosphorylated Stat5 level in spleen at 30 mg/kg, po after 12 hrs by Western blotting 21138246
HEL Function assay 0.3 uM 5 mins Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting 21138246
HEL Function assay 0.3 uM 30 to 60 mins Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting 21138246
Hs578T Function assay 1 uM 24 hrs Inhibition of STAT3C-mediated transcription in human Hs578T cells at 1 uM after 24 hrs by luciferase reporter gene assay 24978112
NCI-H1975 Function assay 0.003 to 3 uM 2 hrs Inhibition of JAK1 in human NCI-H1975 cells assessed as reduction in STAT3 phosphorylation at 0.003 to 3 uM after 2 hrs by Western blot analysis 26614408
PALJDL Cell Viability Assay 72 h IC50=2.4 μM 25504635
AKRSL Cell Viability Assay 72 h IC50＞10 μM 25504635
PCI-15B Growth Inhibition Assay 72 h EC50=0.99 ± 1.74 μM 25810010
PCI-52 Growth Inhibition Assay 72 h EC50=1.00 ± 0.09 μM 25810010
OSC19 Growth Inhibition Assay 72 h EC50=1.26 ± 0.20 μM 25810010
UM-22A Growth Inhibition Assay 72 h EC50=1.32 ± 0.39 μM 25810010
UM SCC-1 Growth Inhibition Assay 72 h EC50=1.67 ± 0.42 μM 25810010
686LN Growth Inhibition Assay 72 h EC50=2.05 ± 1.33 μM 25810010
UM-22B Growth Inhibition Assay 72 h EC50=2.66 ± 0.24 μM 25810010
Cal33 Growth Inhibition Assay 72 h EC50=3.37 ± 0.75 μM 25810010
HN5 Growth Inhibition Assay 72 h EC50=3.81 ± 1.99 μM 25810010
HD-LM2 Growth Inhibition Assay 72 h IC50=7.844 μM 22829094
L-428 Growth Inhibition Assay 72 h IC50=7.947 μM 22829094
KM-H2 Growth Inhibition Assay 72 h IC50=1.308 μM 22829094
L-540 Growth Inhibition Assay 72 h IC50=8.216 μM 22829094
SET2 Growth inhibition assay 48 hrs Growth inhibition of human SET2 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.016 μM. 21138246
SET2 Function assay 1 hr Inhibition of Stat3 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.023 μM. 21138246
SET2 Function assay 1 hr Inhibition of Stat5 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.025 μM. 21138246
HEL Function assay 1 hr Inhibition of Stat5 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.041 μM. 21138246
UKE1 Growth inhibition assay 48 hrs Growth inhibition of human UKE1 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.054 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK2 kinase after 48 hrs by MTS assay, GI50 = 0.06 μM. 21138246
HEL Function assay 1 hr Inhibition of Stat3 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.08 μM. 21138246
HEL Growth inhibition assay 48 hrs Growth inhibition of human HEL cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.39 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK1 kinase after 48 hrs by MTS assay, GI50 = 0.7 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-Tyk2 kinase after 48 hrs by MTS assay, GI50 = 2 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK3 kinase after 48 hrs by MTS assay, GI50 = 2.1 μM. 21138246
UKE1 Function assay 1 hr Inhibition of Stat5 phosphorylation in human UKE1 cells after 1 hr by Western blotting 21138246
HEL 92.1.7 Function assay 2 hrs Inhibition of JAK2 in human HEL 92.1.7 cells assessed as reduction in STAT5 phosphorylation after 2 hrs by Western blot analysis 26614408
IMR32 Growth Inhibition Assay IC50=0.66 μM 23531921
NGP Growth Inhibition Assay IC50=0.56 μM 23531921
AS Growth Inhibition Assay IC50=1.53 μM 23531921
BE2 Growth Inhibition Assay IC50=0.71 μM 23531921
SY5Y Growth Inhibition Assay IC50=0.36 μM 23531921
KCNR Growth Inhibition Assay IC50=0.46 μM 23531921
HEK293 Growth Inhibition Assay IC50=8.67 μM 23531921
ARPE19 Growth Inhibition Assay IC50=24.38 μM 23531921
RC165N Apoptosis Assay IC50=2.083 μM 23942095
DU145 Apoptosis Assay IC50=3.517 μM 23942095
PC-3 Apoptosis Assay IC50=1.755 μM 23942095
CWR22Pc Apoptosis Assay IC50=0.438 μM 23942095
CWR22Rv1  Apoptosis Assay IC50=0.482 μM 23942095
DMS114 Growth Inhibition Assay IC50=0.73 μM 24158701
H1173 Growth Inhibition Assay IC50=2.39 μM 24158701
H526 Growth Inhibition Assay IC50=3.08 μM 24158701
GLC4 Growth Inhibition Assay IC50=1.79 μM 24158701
H82 Growth Inhibition Assay IC50=1.37 μM 24158701
N592 Growth Inhibition Assay IC50=0.84 μM 24158701
LAN5 Growth Inhibition Assay IC50=1.04 μM 23531921
RH18 Growth Inhibition Assay IC50=1.42 μM 23531921
RH30 Growth Inhibition Assay IC50=1.25 μM 23531921
RH17 Growth Inhibition Assay IC50=2.51 μM 23531921
RH28 Growth Inhibition Assay IC50=4.28 μM 23531921
RH36 Growth Inhibition Assay IC50=5.37 μM 23531921
RH41 Growth Inhibition Assay IC50=0.48 μM 23531921
RD Growth Inhibition Assay IC50=4.32 μM 23531921
TC32 Growth Inhibition Assay IC50=3.85 μM 23531921
TC71 Growth Inhibition Assay IC50=4.33 μM 23531921
Ba/F3 Function assay Inhibition of Stat5 phosphorylation in mouse Ba/F3 cells expressing TEL-Jak2, IC50 = 0.046 μM. 21138246
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
点击查看更多细胞系数据

生物活性

产品描述 AZD1480是一种新型，ATP竞争性的JAK2抑制剂，无细胞试验中IC50为0.26 nM，选择性作用于JAK3和Tyk2，对JAK1的作用较弱。Phase 1。
特性 AZD1480为治疗多发性骨髓瘤的潜在新型治疗剂。
靶点
JAK2 [1]
(Cell-free assay)
0.26 nM
体外研究(In Vitro)
体外研究活性 5μM AZD1480诱导细胞周期停在G2/M期，且通过抑制Aurora激酶而诱导细胞死亡。[1]AZD1480是JAK2的有效抑制剂，作用于人类多发性骨髓瘤细胞，可以抑制生长，存活，FGFR3 和 STAT3信号，及下游靶点，包括 Cyclin D2。在低微摩尔浓度时，AZD1480抑制细胞增殖和诱导骨髓瘤细胞系凋亡。[2]AZD1480 作用于人和鼠神经胶质瘤细胞，有效抑制组成型和诱导型JAK1, JAK2, 及STAT-3的磷酸化作用 ，结果导致细胞增殖降低，且诱导凋亡。[3]AZD1480是有效的ATP竞争性的JAK1/2激酶小分子抑制剂，可抑制STAT3磷酸化和肿瘤生长，这种抑制存在STAT3依赖性。AZD1480通过影响肿瘤的微环境而抑制肿瘤血管生成和局部转移。[4]
激酶实验 激酶实验
在有buffer(包括50 mM HEPES pH 为7.3, 1 mM DTT, 0.01% Tween-20, 50 µg/ml BSA,及10 mM MgCl2)的条件下，使用重组Jak1, Jak2, 或Jak3进行AZD1480抑制效果研究。在昆虫细胞中，Jak3酶表达为氮端GST融合蛋白，且通过谷胱甘肽亲和及尺寸排除色谱来纯化Jak3酶。加入AZD1480 (10点剂量反应, 重复三次, 8.3 µM 到0.3 nM )，使用1.5 µM 肽底物(Jak1:FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2和Jak3: FAM-SRCtide)，及各自ATP Km (Jak1: 55 µM, Jak2: 15 µM, Jak3: 3 µM)，ATP浓度为5 mM，进行酶实验。分离磷酸化和未磷酸化的肽段，使用Caliper LC3000系统计算抑制百分率。
细胞实验 细胞系 Renca或786-O细胞，鼠内皮细胞和脾CD11b+/c−骨髓细胞, HUVECs
浓度 1 μM
孵育时间 48或24小时
方法 Renca或786-O细胞悬浮在含5%FBS的DMEM培养基中,按每孔5×103个细胞接种在96孔板上，使细胞粘附，实验组用AZD1480，对照组用DMSO，处理48小时。通过MTS实验测定细胞活力。使用Mikrotek Laborsysteme在490nm处测定吸光值。鼠内皮细胞和脾CD11b+/c− 骨髓细胞从携带肿瘤的鼠中富集得到，培养在含5% FBS的RPMI-1640培养基上。HUVECs 培养在胶原1包被的含完全培养基的板上。用DMSO和不同剂量AZD1480处理所有细胞，持续24小时。手动计算细胞数而测定细胞活力。所有实验重复三次。
实验图片 检测方法 检测指标 实验图片 PMID
Western blot p-STAT3 / STAT3 / p-JAK2 / JAK2 p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2 22027691
Immunofluorescence pSTAT5 30140255
Growth inhibition assay Cell proliferation Cell viability 22027691
体内研究(In Vivo)
体内研究活性 AZD1480作用于人类实体瘤模型和多发性骨髓瘤模型，抑制 STAT3磷酸化。[1]在体内, AZD1480抑制皮下移植瘤的生长，且通过抑制STAT3活性提高携带颅内恶性胶质瘤(GBM)的鼠寿命，说明AZD1480抑制JAK/STAT3通路的药理学可以用于研究治疗携带颅内恶性胶质瘤的患者。[3]AZD1480抑制骨髓细胞的肺浸润和肺转移瘤。AZD1480作用于人类移植瘤模型降低血管生成和代谢。[4]AZD1480抑制含有STAT活性的人类实体瘤的生长。[5]
动物实验 Animal Models 雌性BALB/c和无胸腺鼠(NCR− nu/nu) (7-8周大)
Dosages 每天一次，剂量为50 mg/kg；或者每天两次，剂量为30 mg/kg
Administration 口服饲喂
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01219543 Terminated
Solid Tumour|Advanced Solid Malignancies|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma|EGFR and/or ROS Mutant NSCLC|Lung Metastasis Carcinoma|Gastric Cancer
AstraZeneca
 November 2010 Phase 1
NCT01112397 Terminated
Solid Malignancies
AstraZeneca
 April 2010 Phase 1
  • http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255510/
  • https://pubmed.ncbi.nlm.nih.gov/21164517/
  • https://pubmed.ncbi.nlm.nih.gov/22027691/
  • https://pubmed.ncbi.nlm.nih.gov/21920898/
  • https://pubmed.ncbi.nlm.nih.gov/19962667/

化学信息&溶解度

分子量 348.77 分子式

C14H14ClFN8
CAS号 935666-88-9 SDF Download AZD1480 SDF
Smiles CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F
储存条件(自收到货起)

体外溶解度
批次：

DMSO : 70 mg/mL ( (200.7 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解配方
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

 动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

mg/kg g μL 只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
在线咨询
联系我们